Australian Clinical Labs Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACL.AX research report →
Price Chart
About the company
Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services.
- CEO
- Melinda McGrath
- IPO
- 2021
- Employees
- 4,500
- HQ
- Clayton, VIC, AU
Get TickerSpark's AI analysis on ACL.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $552.10M
- P/E
- 23.95
- Fwd P/E
- 15.82
- PEG
- -0.72
- P/S
- 0.76
- P/B
- 3.79
- EV/EBITDA
- 4.46
- Div Yield
- 4.31%
- Gross Margin
- 20.59%
- Op Margin
- 8.04%
- Net Margin
- 3.25%
- ROE
- 15.80%
- ROIC
- 7.67%
Latest fiscal year · YoY change
- Revenue
- $729.52M-1.6%
- Gross Profit
- $150.21M-44.5%
- Op Income
- $61.49M
- Net Income
- $23.71M-26.9%
- EPS
- $0.12-29.4%
- OCF Growth
- -10.7%
- FCF Growth
- -11.8%
- 52W High
- $2.98
- 52W Low
- $1.83
- 50D MA
- $2.35
- 200D MA
- $2.34
- Beta
- 0.81
- RSI (14)
- 79
- Avg Volume
- 656.78K
No earnings-call transcripts are available for ACL.AX yet.
- Free Float
- 93.1%
- Shares Outstanding
- 186.52M
- Float Shares
- 173.63M
Held by 65 ETFs
Biggest fund positions in ACL.AX by dollar value.
Our ACL.AX coverage
Recent articles, reports, and earnings notes.
No research on ACL.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACL.AX report →